Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817203 | 0.85 | LCLAT1 (0.49) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL1499540 | 0.85 | GRM4 (0.68) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL1811042 | 0.82 | KCNK3 (0.60) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL16007625 | 0.80 | MEN1 (0.76) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL30928884 | 0.79 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL30928885 | 0.79 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL29250728 | 0.79 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL23367919 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL25872154 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL1805499 | 0.77 | MEN1 (0.67) | ALDH1A1MEN1KMT2AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2318358-A2 | ACYLAMINOBENZAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010015355-A2 | NOVEL ACYLAMINOBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | KCNB1, KCNA5, KCNA7 | ALDH1A1 271/4885MEN1 3469/4885KMT2A 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.